Laboratorios Rovi : Q3 2022 results miss on weaker vaccine momentum. Downbeat FY 2023 sales guidance
>Sales momentum improves slightly q-o-q yet misses our estimates - Total revenues increased 12% y-o-y in Q3 2022 reaching € 194m missing our estimates and consensus by -3% and -9% respectively despite posting a 3pp sequential improvement. The miss is namely due to a slowdown in toll manufacturing sales to Moderna for its mRNA Covid vaccine vs previous quarters (sales of toll manufacturing +18% y-o-y to € 102m vs +167% growth posted in Q1 2022 and +21% in Q2 2022). Mea...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.